NASDAQ: BIAFBioaffinity Technologies Inc Stock
$0.71-0.01 (-1.39%)
Updated Jul 16, 2026
BIAF Price
$0.71
Fair Value Price
N/A
Market Cap
$3.23M
52 Week Low
$0.61
52 Week High
$13.50
P/E
-0.06x
P/B
0.88x
P/S
3.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.66M
Earnings
-$15.88M
Gross Margin
33.1%
Operating Margin
-279.17%
Profit Margin
-280.6%
Debt to Equity
1.17
Operating Cash Flow
-$11M
Beta
1.47
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BIAF Overview
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIAF's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
BIAF
Ranked#38 of 43
Ranked#38 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $40.34 | A | |
| $18.27 | B | |
| $128.18 | B |
Be the first to know about important BIAF news, forecast changes, insider trades & much more!
BIAF News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIAF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIAF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIAF is good value based on its book value relative to its share price (0.88x), compared to the US Diagnostics & Research industry average (3.98x)
P/B vs Industry Valuation
BIAF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIAF due diligence checks available for Premium users.
Valuation
BIAF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
15.02x
Market
11.26x
BIAF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
3.98x
BIAF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIAF's financial health
Profit margin
Revenue
$1.4M
Net Income
-$3.6M
Profit Margin
-268.6%
BIAF's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIAF's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.9M
Liabilities
$4.3M
Debt to equity
1.17
BIAF's short-term assets ($4.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIAF's short-term assets ($4.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIAF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
-$5.7k
Financing
-$118.5k
BIAF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIAF vs Diagnostic & Research Stocks
Bioaffinity Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.